[ad_1]
Chinese Ambassador Huang Xilian revealed in a statement on September 8 that around 1,500 Filipinos have participated in the world’s first Phase 3 clinical trial of the Covid-19 vaccine conducted by developer Sinopharm in the United Arab Emirates since 23 September. June.
Sinopharm has also launched Phase 3 clinical research in a few other countries, including Bahrain, Argentina, Peru, and Morocco, involving more than 50,000 volunteers from 115 countries with leading advances in all aspects.
Ambassador Huang further explained that hundreds of thousands of people have received Sinopharm vaccine vaccinations since China launched the emergency use of Covid-19 vaccines on July 22, with no cases of infection or serious adverse effects. Relevant tests of the Sinopharm vaccine against major Covid-19 virus strains, including those from Beijing Xinfadi and other regions of Russia, the United Kingdom, the United States, Austria, etc., showed promising results both in terms of safety and efficacy.
The ambassador also revealed that, according to Sinopharm, the vaccine is likely to be on the market by the end of December, and the company has built two high-end biosafety production facilities in both Beijing and Wuhan, with annual production capacity. of 300 million. dose. With the expansion of the production capacity, the annual production will reach 800 million to 1 billion doses in the future.
Since the Covid-19 outbreak, China has been actively participating in vaccine research and development. So far, the World Health Organization has registered 34 candidate vaccines that are under clinical evaluation around the world. And now there are eight candidate vaccines in the Phase 3 trial, which is the final phase before commercial use, and four candidate vaccines are from Chinese vaccine developers, including two from Sinopharm, a subsidiary of China’s main vaccine producer China National. Pharmaceutical Group (CNBG). , one from Sinovac Biotech and one from CanSino Biological.
[ad_2]
